AU Patent

AU2002328956B2 — 17alfa, 21-dihydroxypregnene esters as antiandrogenic agents

Assigned to Cassiopea SpA · Expires 2007-08-16 · 19y expired

What this patent protects

The present application provides 17 and/or 21 esters of 17α,21-Dihydroxypregna-4,9(11)-diene-3,20-dione and 17α,21-dihydroxypregna-4-ene-3,20-dione having remarkable antiandrogenic activity, methods of using these compounds, and processes for their preparation.

USPTO Abstract

The present application provides 17 and/or 21 esters of 17α,21-Dihydroxypregna-4,9(11)-diene-3,20-dione and 17α,21-dihydroxypregna-4-ene-3,20-dione having remarkable antiandrogenic activity, methods of using these compounds, and processes for their preparation.

Drugs covered by this patent

Patent Metadata

Patent number
AU2002328956B2
Jurisdiction
AU
Classification
—
Expires
2007-08-16
Drug substance claim
No
Drug product claim
No
Assignee
Cassiopea SpA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.